FibroGen, Inc. (FGEN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
FibroGen, Inc. (FGEN) trades at $9.07 with AI Score 46/100 (Grade C). FibroGen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for serious unmet medical needs. Market cap: $36.69M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for FGEN: FGEN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FGEN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FGEN: the 1 perspectives are evenly split.
How is this calculated? →FibroGen, Inc. (FGEN) Healthcare & Pipeline Overview
FibroGen, Inc. is a biopharmaceutical company specializing in therapeutics for anemia and fibrosis-related diseases. Their lead product, Roxadustat, addresses anemia in chronic kidney disease, while Pamrevlumab targets idiopathic pulmonary fibrosis and other fibrotic conditions. The company operates through strategic collaborations with Astellas and AstraZeneca.
What Is the Investment Thesis for FGEN?
FibroGen's investment thesis hinges on the successful commercialization of Roxadustat and the clinical advancement of Pamrevlumab. Roxadustat's potential in the anemia market, particularly for chronic kidney disease patients, represents a significant revenue opportunity. The company's strategic partnerships with Astellas and AstraZeneca provide financial support and market access. Pamrevlumab's Phase III trials across multiple fibrotic indications, including IPF and pancreatic cancer, offer substantial upside potential if clinical endpoints are met. However, regulatory hurdles, clinical trial outcomes, and competition in the biotechnology sector pose risks. The company's current market capitalization of $36.69M reflects both the potential and the risks associated with its pipeline.
Based on FMP financials and quantitative analysis
FGEN Key Highlights
- Market capitalization of $36.69M indicates the company's current valuation in the market.
- P/E ratio of 0.2 suggests the company is generating earnings relative to its stock price.
- Profit margin of 2848.2% highlights strong profitability, potentially from licensing or collaboration revenues.
- Gross margin of 75.8% reflects efficient cost management in product development and manufacturing.
- Beta of 0.77 indicates lower volatility compared to the overall market, suggesting a more stable investment.
Who Are FGEN's Competitors?
FGEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FGEN's Key Strengths?
- Proprietary drug candidates targeting unmet medical needs.
- Positive clinical trial data for Roxadustat and Pamrevlumab.
- Strategic collaborations with Astellas and AstraZeneca.
- Experienced management team with expertise in drug development.
What Are FGEN's Weaknesses?
- Reliance on a limited number of key products.
- High R&D expenses and long development timelines.
- Dependence on regulatory approvals for commercialization.
- Relatively small market capitalization compared to competitors.
What Could Drive FGEN Stock Higher?
- Potential regulatory approvals for Pamrevlumab in IPF, pancreatic cancer, liver fibrosis, diabetic kidney disease, and Duchenne muscular dystrophy.
- Continued commercialization and market penetration of Roxadustat in approved regions.
- Data readouts from ongoing clinical trials for Pamrevlumab.
- Announcement of new strategic collaborations or partnerships.
What Are the Key Risks for FGEN?
- Financial-distress signal — its Altman Z-Score of -21.89 sits in the distress zone (elevated bankruptcy risk).
- Failure to obtain regulatory approvals for Roxadustat or Pamrevlumab in key markets.
- Unfavorable clinical trial results for Pamrevlumab.
- Competition from established pharmaceutical companies and generic drugs.
- Dependence on strategic collaborations for revenue and market access.
- Patent expirations and intellectual property challenges.
What Are the Growth Opportunities for FGEN?
- Expansion of Roxadustat into new markets: Roxadustat has already been approved in several regions, including China and Japan. Further expansion into additional markets, such as emerging economies with growing CKD populations, represents a significant growth opportunity. This expansion could increase revenue streams and solidify FibroGen's global presence in the anemia treatment market. Timeline: Ongoing.
- Advancement of Pamrevlumab through clinical trials: Pamrevlumab is currently in Phase III clinical development for multiple indications, including IPF, pancreatic cancer, liver fibrosis, diabetic kidney disease and Duchenne muscular dystrophy. Positive clinical trial results and subsequent regulatory approvals could significantly expand the drug's market potential and drive revenue growth. The market for IPF treatments alone is projected to reach billions of dollars. Timeline: 2027-2028.
- Strategic collaborations and partnerships: FibroGen's existing collaborations with Astellas and AstraZeneca provide financial support and market access. Pursuing additional strategic partnerships with other pharmaceutical companies or research institutions could further accelerate the development and commercialization of its pipeline products. These collaborations can also provide access to new technologies and expertise. Timeline: Ongoing.
- Development of new therapeutic candidates: FibroGen can leverage its expertise in fibrosis and anemia to develop new therapeutic candidates targeting other unmet medical needs. This could involve exploring new drug targets, developing novel drug delivery systems, or expanding into new therapeutic areas. A diversified pipeline reduces the company's reliance on its lead products and enhances its long-term growth prospects. Timeline: 3-5 years.
- Exploration of combination therapies: Combining Roxadustat or Pamrevlumab with other existing therapies could enhance their efficacy and expand their therapeutic applications. For example, combining Pamrevlumab with other anti-fibrotic agents could provide a more comprehensive treatment approach for IPF. Exploring these combination therapies could create new market opportunities and improve patient outcomes. Timeline: 2-3 years.
What Opportunities Does FGEN Have?
- Expansion of Roxadustat into new markets and indications.
- Successful clinical development and approval of Pamrevlumab.
- Further strategic collaborations and partnerships.
- Development of new therapeutic candidates and technologies.
What Threats Does FGEN Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and potential for clinical trial failures.
- Patent expirations and generic competition.
- Economic downturns and changes in healthcare policies.
What Are FGEN's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Established clinical data supporting the efficacy of Roxadustat and Pamrevlumab.
- Strategic partnerships with major pharmaceutical companies.
- Expertise in developing therapeutics for anemia and fibrotic diseases.
What Does FGEN Do?
FibroGen, Inc., founded in 1993 and headquartered in San Francisco, California, is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics for serious unmet medical needs. The company's primary focus is on addressing anemia and fibrotic diseases. Its lead product candidate, Roxadustat, is an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylases (HIF-PH). Roxadustat has completed Phase III clinical development for treating anemia in chronic kidney disease (CKD) across the United States, Europe, China, and Japan. Additionally, it is in Phase II/III development in China for anemia associated with myelodysplastic syndromes (MDS). FibroGen is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF). Pamrevlumab is currently in Phase III clinical development for treating idiopathic pulmonary fibrosis (IPF), pancreatic cancer, liver fibrosis, diabetic kidney disease, and Duchenne muscular dystrophy (DMD). The company operates through strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB to develop and commercialize its products in various global markets. FibroGen's research and development efforts are aimed at providing innovative treatments for patients with limited therapeutic options.
What Products and Services Does FGEN Offer?
- Discovers and develops therapeutics for unmet medical needs.
- Focuses on treatments for anemia and fibrotic diseases.
- Develops Roxadustat, an oral treatment for anemia in chronic kidney disease.
- Develops Pamrevlumab, a monoclonal antibody for fibrotic diseases like IPF.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approvals for its products in various global markets.
- Collaborates with pharmaceutical companies like Astellas and AstraZeneca.
How Does FGEN Make Money?
- Develops and patents novel therapeutic candidates.
- Conducts clinical trials to demonstrate efficacy and safety.
- Out-licenses or co-develops products with larger pharmaceutical companies.
- Generates revenue through milestone payments, royalties, and product sales.
What Industry Does FGEN Operate In?
FibroGen operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for anemia treatments, particularly in chronic kidney disease, is substantial and growing, driven by an aging population and increasing prevalence of CKD. The fibrosis market, including IPF and liver fibrosis, also represents a significant unmet medical need with limited treatment options. FibroGen competes with established pharmaceutical companies and other biotechnology firms developing novel therapies in these areas. Success in this industry requires strong scientific expertise, successful clinical trials, and effective commercialization strategies.
Who Are FGEN's Key Customers?
- Patients with anemia associated with chronic kidney disease.
- Patients with idiopathic pulmonary fibrosis (IPF).
- Patients with pancreatic cancer, liver fibrosis, and diabetic kidney disease.
- Pharmaceutical companies like Astellas and AstraZeneca through collaboration agreements.
How FibroGen, Inc. Is Valued
FibroGen, Inc. carries a market capitalization of $36.69M, placing it in the micro-cap category. Relative to its peer group, FGEN's quantitative score of 46/100 is below the peer average of 85/100.
P/E 0.2Key Financial Metrics
FGEN trades at a trailing price-to-earnings ratio of 0.17, below the Healthcare sector average of ~23x. Its free cash flow yield is -70.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.61 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 6/9Financial Health
FibroGen, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -21.89 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project FibroGen, Inc. revenue of about $6.1M for fiscal 2026, with EPS near $-11.95.
FGEN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- FibroGen's recent insider buying suggests confidence in the company's future prospects, aligning with a potential turnaround narrative. Community sentiment leans bullish, fueled by hopes for their pipeline. The market seems cautiously optimistic about their drug development progress, especially given recent regulatory interactions. Positive discussions within the community highlight belief in FibroGen's long-term potential and innovation in their therapeutic areas.
Bear Case
- Recent community discussions reveal concerns about FibroGen's past controversies and their potential impact on future approvals. Negative sentiment persists due to lingering doubts about the efficacy and safety of their key drug. Market perception remains skeptical, with analysts questioning the company's ability to regain trust. Insider selling, even if minor, could contribute to bearish sentiment within the trading community, signaling uncertainty about the company's short-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
FGEN Latest News
No recent news available for FGEN.
FGEN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FGEN.
Price Targets
Wall Street price target analysis for FGEN.
FGEN MoonshotScore
What does this score mean?
The MoonshotScore rates FGEN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thane Wettig
CEO
Thane Wettig serves as the Chief Executive Officer of FibroGen, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on strategic leadership and operational management. Wettig has held various leadership positions in pharmaceutical and biotechnology companies, contributing to drug development and commercialization efforts. His expertise spans across multiple therapeutic areas, including oncology and cardiovascular diseases. He is responsible for guiding FibroGen's overall strategy and ensuring the company's continued growth and success.
Track Record: Under Thane Wettig's leadership, FibroGen has focused on advancing its pipeline, particularly Roxadustat and Pamrevlumab, through clinical development. He has overseen strategic collaborations with Astellas and AstraZeneca, which have been crucial for the commercialization and development of FibroGen's products. Wettig has also worked to strengthen the company's financial position and expand its research and development capabilities.
Common Questions About FGEN (Healthcare)
What does FibroGen, Inc. do?
FibroGen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for serious unmet medical needs. The company's primary focus is on treating anemia and fibrotic diseases. Its lead product, Roxadustat, is an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylases (HIF-PH), used for treating anemia in chronic kidney disease. FibroGen is also developing Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor (CTGF), for treating idiopathic pulmonary fibrosis and other fibrotic conditions. The company collaborates with Astellas and AstraZeneca to develop and commercialize its products globally.
What do analysts say about FGEN stock?
Analyst coverage of FibroGen (FGEN) is mixed, reflecting the inherent risks and potential rewards associated with biotechnology companies. Key valuation metrics, such as the P/E ratio of 0.2, suggest that the company is generating earnings. However, the company's future growth prospects are closely tied to the successful commercialization of Roxadustat and the clinical advancement of Pamrevlumab. Analyst opinions often hinge on the outcomes of ongoing clinical trials and regulatory decisions. Investors should conduct their own due diligence and consider their risk tolerance before investing in FGEN.
What are the main risks for FGEN?
FibroGen faces several key risks inherent to the biotechnology industry. Clinical trial failures for Pamrevlumab could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining approvals for Roxadustat and Pamrevlumab pose another significant risk. Competition from established pharmaceutical companies and the potential for generic erosion also present challenges. Additionally, FibroGen's reliance on strategic collaborations with Astellas and AstraZeneca exposes the company to counterparty risk. Patent expirations and intellectual property disputes could also negatively affect the company's competitive position.
What are the key factors to evaluate for FGEN?
FibroGen, Inc. (FGEN) holds an AI score of 46/100 (low). P/E: 0.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does FGEN data refresh on this page?
FGEN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven FGEN's recent stock price performance?
FibroGen, Inc. (FGEN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug candidates targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FGEN overvalued or undervalued right now?
FibroGen, Inc. (FGEN) trades at 0.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying FGEN?
Before investing in FibroGen, Inc. (FGEN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial situation.